stockrowImmunome, Inc.
IMNM Healthcare Biotechnology
Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.
- Revenue
- +69.8%
- EPS
- −30.0%
- Free cash flow
- −27.0%
Quarter to June 2026, against a year earlier
Follow IMNM
Alert me
Immunome, Inc. (IMNM) Book value per share
Immunome, Inc.'s book value per share at the end of fiscal 2025 was 7.3×, up 135.1% from 3.1× in fiscal 2024. At the end of the quarter to 30 June 2026 it was 4.6×. Over the past ten years it has ranged from 1.4× (fiscal 2022) to 12.2× (fiscal 2020); the current reading is higher than 88% of that period. Immunome, Inc. ranks 163rd of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 7.3× | 135.05% |
| FY2024 | 3.1× | (48.86%) |
| FY2023 | 6.0× | 339.94% |
| FY2022 | 1.4× | (67.12%) |
| FY2021 | 4.2× | (65.76%) |
| FY2020 | 12.2× | 308.79% |
| FY2019 | 3.0× | 40.51% |
| FY2018 | 2.1× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Jun 2026 | 4.6× | (10.91%) |
| Mar 2026 | 5.2× | (28.35%) |
| Dec 2025 | 7.3× | 142.03% |
| Sep 2025 | 3.0× | (3.04%) |
| 25 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | 15.1× |
| CLDX Celldex Therapeutics, Inc. compare | 9.2× |
| VCEL Vericel Corporation compare | 7.5× |
| VERA Vera Therapeutics, Inc. compare | 5.7× |
| AUPH Aurinia Pharmaceuticals Inc compare | 4.9× |
| IMNM Immunome, Inc. | 4.6× |
| ADMA ADMA Biologics Inc compare | 2.0× |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | 0.0× |
| BHVN Biohaven Ltd. compare | −0.7× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on IMNM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Altman Z-score
- The full statement